Introduction

Methodology

d, a c b d, c c a l, ac d a c l, ac l, a d l, ac l, ac

 a a, c. d₁, cac.

Drug safety monitoring: P. a_1 ac, d_2 a, c_3 a..., c_4 a, c_4 a

Combination therapy: I, , , d, a , , c, b, a, , , , (a , a b , , , , d, , a , , , , , . , a , . , P, a, ac, d , a , c , , c , a , , d , , , d , , , ac a , , , c , , , a d , , , d , , , ac , , , , ac , , , , . , ac , , , , . .

Conclusion

P. av. ac, d. a., c., ac, i., i., b. d. B. .., d., i., d., ...
b. d. i. c., i. a., dac, a., i., b. b., ..., ca i., c., i. av. i., a., d., ..., cac, ..., d., c., a., d., ..., ac, d., a., ..., ac, d., ..., ac, ...

References

1. McLeod HL (1998) Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 45:539-544.

- 2. Ma J, Verweij J, Planting AS, Kolker HJ, Loos WJ, et al. (1996) Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 37:382-384.
- 3. Ando M, Saka H, Ando Y, Minami H, Kuzuya T, et al. (2005) Sequence efect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences. Cancer Chemother Pharmacol 55:552-558.
- 4. Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, et al. (2015) Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. Chem Res , et al